Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEWARK, N.J., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease (AD), today...
-
NEWARK, N.J., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease, today announced...
-
NEWARK, N.J., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP) today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate,...
-
NEWARK, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP) today announced that its Chief Scientific Officer, Dr. Daniel Alkon, has been invited to present on a panel focused on new...
-
NEWARK, N.J., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (OTCBB:NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial...
-
NEWARK, N.J., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (OTCBB:NTRP) today announced the initiation of a Phase 2b clinical trial of lead candidate Bryostatin 1 for the treatment of...